Professor of Hematology and Oncology, University MD School of Medicine
Hematology
Dr. Maria Baer, MD
|
|
Give Review
Maria Baer works in the field of Hematology. He went to medical school at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He over the years received 7 awards: "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Super Doctor" and "Whos Who in Medicine and Healthcare". Maria Baer is a published doctor. He has 33 publications published. The most current publication "Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy." Dr. Maria Baer accepts Medicare payments and is listed with Medicare.gov.
Publications
- Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part d.
- The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant ...
- Treatment of Philadelphia chromosome-positive Acute lymphoblastic leukemia in pregnancy.
- Disparities in black and white patients with multiple Myeloma referred for autologous hematopoietic transplantation: A single center study.
- Expression and prognostic impact of lncRNAs in Acute myeloid leukemia.
- Lack of objective response of myelodysplastic syndromes and Acute myeloid leukemia to decitabine after failure of azacitidine.
- Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary Acute myeloid leukemia.
- Prognostic gene mutations and distinct gene- and microRNA-expression signatures in Acute myeloid leukemia witha sole trisomy 8.
- Ten-day decitabine as initial therapy for newly diagnosed patients with Acute myeloid leukemia unfit for intensive chemotherapy.
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
- Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with Myelodysplastic syndromes.
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in Acute leukemias.
- Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic Leukemia.
- Cryptic chromosome abnormalities in a patient with mixed phenotype Acute leukemia.
- Unbalanced 11;18 translocation in an Acute erythroid leukemia after radioactive iodine therapy.
- Treatment and outcomes for chronic myelomonocytic Leukemia compared to myelodysplastic syndromes in older adults.
- Outcome of older patients with Acute myeloid leukemia: An Analysis of SEER Data Over 3 Decades.
- Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid Leukemias.
- Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with Myelodysplastic syndromes and consistency with clinical guidelines.
- Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk ...
- Phase I study of UCN-01 and perifosine in patients with relapsed and refractory Acute leukemias and high-risk myelodysplastic syndrome.
- The Pim kinase inhibitor SGI-1776 decreases Cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-...
- Tertiary center referral patterns for patients with Myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.
- Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma.
- Scedosporium apiospermum Soft Tissue Infection as the Initial Presentation of Acute Myeloid Leukemia: A Case Report.
- The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.
- Natural history of osteonecrosis of the jaw in patients with multiple Myeloma.
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with Acute myeloid leukemia in first complete remission: Cancer and Le...
- High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal Acute myeloid leukemia with FLT3 internal tandem duplication.
- Effect of erythropoiesis-stimulating agent policy decisions on off-label use in Myelodysplastic syndromes.
- Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication.
- The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions.
Schools
Johns Hopkins University School of Medicine
Vanderbilt University Hospital
Vanderbilt University
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Select
- Amerigroup (Wellpoint)
- Assurant Health
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Southern Health PPO
- Coventry Health Care of Delaware PPO
- GHI PPO
- Health Insurance Plan of Greater New York (HIP) PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- Golden Rule
- HealthPartners
- Choice Care PPO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Maryland Physicians Care
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
Vanderbilt University -
Johns Hopkins University School of Medicine
Hospital
-
University of Maryland Baltimore Washington Medical Center -
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1700881802 | |
| NPPES Provider LastName | BAER | |
| NPPES Provider FirstName | MARIA | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology | |
| Total Claim Count | 154.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700881802 |
| Last Name Of The Provider | BAER |
| First Name Of The Provider | MARIA |
| View All |
Similar Doctors
|
|
Dr. Madhu Chaudhry, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerry Spivak, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Josephine L. Feliciano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanford A. Stass, MD |
|
|
Dr. Robert A. Brodsky, MD |
|
|
Dr. Michael J. Purtell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey L. Seibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea C. Baines, MD |
|
|
Dr. Patrick M. Forde, MD |
|
|
Dr. Rutika J. Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nitya P. Raj, MD |
|
|
Dr. Ann B. Zimrin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William B. Dalton, MD |
|
|
Hibba-Tul Rehman, MB BS |